Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
- Written by PR Newswire
![]() |
- Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program
- Aims to strengthen its oncology portfolio with a novel drug candidate for newly identified hits from HitGen's proprietary DEL that are...















